Clinical Trial

Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 18, 2024 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This multicenter, single-arm trial will explore the efficacy and safety of liposomal irinotecan and capecitabine plus bevacizumab as second-line therapy in metastatic colorectal cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-21.
Trial Details
NCT Number NCT06192680
Lead Sponsor Harbin Medical University
Conditions Colorectal Cancer
Enrollment 63 participants
Start Date 2024-04-01
Primary Completion 2025-11-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-01-18